Formycon announces commercial launch of FYB201 (Ranibizumab) in Canada (RanoptoTM) and Switzerland (

EQS-News: Formycon AG / Key word(s): Market LaunchFormycon announces commercial launch of FYB201 (Ranibizumab) in Canada (RanoptoTM) and Switzerland (Ranivisio®) 11.04.2024 / 07:30 CET/CESTThe issuer is solely responsible for the content of this announcement.Press release // April 11, 2024 Formycon announces co...

Related Keywords

Canada ,Frankfurt ,Brandenburg ,Germany ,United Kingdom ,Switzerland ,United States ,Japan ,Munich ,Bayern ,Australia ,America ,Canadian ,Swiss ,British ,Jennifer Pereira ,Nicola Mikulcik ,Larissa Moniz ,Distribution Services ,Teva Canada ,Polpharma Biologics Group ,Genentech Inc ,Teva Pharmaceuticals ,Health Canada ,Teva Pharmaceutical Industries Ltd ,Investor Relations Corporate Communications ,Frankfurt Stock Exchange ,Market Launch ,North America ,Pharmaceutical Industries ,Investor Relations ,Corporate Communications ,British Journal ,Chad Andrews ,Meeting Abstract ,Corporate News ,Regulatory Announcements ,